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Abstract 
Vitamin D inadequacy [total 25(OH)D <50nmol/L] is widespread in athletes. The biologically 
active metabolite, 1,25-dihydroxyvitamin D, may be involved in regulating inflammation although 
in vitro findings have not been consistently replicated in human intervention trials. This study, 
conducted at a latitude of 55ºN, aimed to assess inflammatory biomarkers in Gaelic footballers 
before and after a wintertime vitamin D3 intervention. Samples from a 12-week double-blind, 
randomised, placebo-controlled trial, in which 42 Gaelic footballers received 3000IU (75µg) 
vitamin D3 daily or placebo via oral spray solutions, were analysed for a range of inflammatory 
biomarkers. Cytokines (interleukin-8 and tumour necrosis factor-α), cathelicidin and high 
sensitivity C-reactive protein were quantified by multiplex assay, ELISA and clinical biochemistry 
respectively. White blood cell, lymphocyte and neutrophil concentrations were determined by full 
blood profile. Data on total 25-hydroxyvitamin D, measured by LC-MS/MS, were available from 
the previous study. Vitamin D3 supplementation significantly increased mean total 25-
hydroxyvitamin D concentrations from 47 to 84nmol/L (P=0.006); yet this had no effect on white 
blood cell count (P=0.699), lymphocyte (P=0.694), neutrophil (P=0.594), interleukin-8 
(P=0.334), tumour necrosis factor-α (P=0.587), cathelicidin (P=0.745) or high sensitivity C-
reactive protein concentration (P=0.621) compared to placebo. 12-weeks vitamin D3 
supplementation did not impact the immune profile of Gaelic footballers. This is likely because 
biomarkers were within their respective normal range or at a concentration similar to that of the 
general population at baseline. Future studies are encouraged to use inflammation as their 
primary outcome measure and recruit athletes at risk of compromised immunity. 
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Introduction 
Vitamin D insufficiency and deficiency, defined as a total 25-hydroxyvitamin D concentration 
below 50 and 30nmol/L respectively, is widespread across different sport disciplines and 
geographical locations (Farrokhyar et al., 2015). Aside from the well-established role of vitamin 
D in facilitating calcium absorption, a growing number of in vitro and human studies indicate that 
this steroid pro-hormone is implicated in regulating systemic inflammation through mediating the 
balance of pro-inflammatory T-helper 1 (Th1) and anti-inflammatory T-helper 2 (Th2) derived 
cytokines and enhancing antimicrobial activity (Baeke et al., 2007;Guo et al., 2014;Schleithoff et 
al., 2006). The biologically active vitamin D metabolite, 1,25-dihydroxyvitamin D [1,25(OH)2D] 
and its interaction with the nuclear vitamin D receptor (VDR), which is expressed throughout the 
immune system, forms a retinoid-x-receptor complex that has been shown to trigger 
immunomodulatory actions in vitro through regulation of specific gene transcription factors. 
Immune cells, including macrophages and neutrophils, are also capable of intrinsically 
synthesising 1,25(OH)2D as they express the cytochrome P450 enzyme, 1-α hydroxylase, 
thereby enabling such cells to directly regulate inflammatory processes in their 
microenvironment (Christakos et al., 2013). Furthermore, vitamin D-mediated transcriptional 
regulation may facilitate production of the human cathelicidin (LL-37), an antimicrobial peptide 
that has an important role in innate immunity by negating viral, bacterial and fungal pathogens 
(Gombart, 2009). It is important to recognise that although 1,25(OH)2D can be quantified using a 
variety of assay methods, it is not considered an appropriate measure of vitamin D status or the 
in vivo response to supplementation. This is because 1,25(OH)2D has a short half-life, its 
concentration is tightly regulated and it is not possible to differentiate between 1,25(OH)2D 
synthesised as a result of a supplemental dose and that synthesised locally (Jones, 2008). 
Observational research in the general population has demonstrated that those with severe 
vitamin D deficiency (<25nmol/L) have a higher concentration of circulating Th1 (pro-
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inflammatory) cytokines; compared to those whose total 25(OH)D concentration exceeds 
75nmol/L (Barker et al., 2013b;Laird et al., 2014). Such evidence has led to the hypothesis that 
a total 25(OH)D concentration above 75nmol/L may be necessary in order to yield the purported 
anti-inflammatory actions of vitamin D; a threshold in-line with current Endocrine Society 
recommendations (Hart, 2012;Holick et al., 2011). With regard to athletes, the majority of 
studies investigating vitamin D and associations with inflammation have focused on those 
competing in endurance-based disciplines, owing to their increased risk of exercise-induced 
immunosuppression (He et al., 2016;He et al., 2013;Pedersen and Hoffman-Goetz, 2000;Willis 
et al., 2012). In endurance runners, total 25(OH)D concentration has been inversely correlated 
with the concentration of tumour necrosis factor-α (TNF-α), one of several Th1 cytokines linked 
to the pathogenesis of overtraining syndrome when chronically elevated, although findings have 
not been consistent across all studies (He et al., 2013;Willis et al., 2012). Cross sectional 
research has also demonstrated that the concentration of C-reactive protein (CRP) (a 
quintessential biomarker of systemic inflammation), is associated with vitamin D status and may 
be elevated in those with a total 25(OH)D concentration below 53nmol/L (Amer and Qayyum, 
2012). Nevertheless, this association may not translate into a causal effect of treatment 
(Chandler et al., 2014;Liefaard et al., 2015). LL-37 concentrations have been reported to be 
significantly higher in endurance athletes with a total 25(OH)D concentration >90nmol/L 
compared to <33nmol/L, suggesting that those below the latter cut-off may be at greater risk of 
infection through impaired LL-37 synthesis and a compromised immune response to pathogen 
exposure (He et al., 2013). However observational studies are unable to establish causality 
between total 25(OH)D concentration and inflammation as a diminished total 25(OH)D 
concentration may be the result of a shift in the Th1:Th2 balance rather than the cause (Autier 
et al., 2014;Mangin et al., 2014;Reid et al., 2011). 
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To our knowledge only two RCTs have examined the effects of vitamin D supplementation on 
inflammation in athletes and little is known regarding the effect of vitamin D supplementation on 
inflammation in athletes that compete in interval sports such as Gaelic football (He et al., 
2015;Lewis et al., 2013). Previously studied cohorts were vitamin D sufficient (>50nmol/L) at 
baseline and reported mixed findings however the response to supplementation may be greater 
in those who present with vitamin D insufficiency/deficiency (<50nmol/L) (Didriksen et al., 2013). 
The aim of this study was to characterise inflammation in Gaelic footballers before and after a 
wintertime vitamin D3 intervention by quantifying systemic inflammation, the concentration of 
Th1 and Th2 peripheral cytokines and LL-37. 
Materials and methods 
Study design 
The analysis conducted in this study formed part of a double-blind, randomised, placebo-
controlled trial which took place at the University of Ulster Coleraine between November 2014 
and April 2015 (Todd et al., 2016). All procedures were approved by the University Research 
Ethics Committee (REC/14/0087), registered at www.clinicaltrials.gov (NCT02278172) and 
conducted in accordance to the declaration of Helsinki. Gaelic footballers signed informed 
consent and attended appointments to obtain fasted blood samples. Physical measures were 
taken before and after a 12-week intervention, the detailed methods of which have been 
reported previously (Todd et al., 2016). 
 
Participants 
Gaelic footballers completed a screening questionnaire to determine eligibility and were 
provided with a study information sheet. Those that were over the age of 18 years and 
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apparently healthy were considered suitable for inclusion. Exclusion criteria were as follows: not 
a member of a University/local sports team; vitamin D supplementation and/or iron 
supplementation in the 30 days prior to baseline measurements; health concern(s)/physical 
disabilities as identified by the screening questionnaire that would prevent successful 
completion of the study; consumption of medication(s) known to influence vitamin D 
metabolism; those following a vegan diet; sun-bed users; those planning a sun holiday during 
the study or had been on a sun holiday in the 30 days prior to baseline measurements. In total, 
42 footballers were deemed eligible for participation and were contacted via e-mail and 
telephone to arrange a date and time for their initial appointment. Aside from vitamin D 
inadequacy, recruited footballers were healthy individuals. This was confirmed through 
completion of a health screening questionnaire as part of the original study. 
Supplements and compliance 
The clinical trials manager randomised footballers to either a vitamin D3 treatment (VD) or 
placebo group (PL). Researchers and athletes remained blinded to the treatment allocation until 
the study and data analyses were complete. Those allocated to VD received an oral spray 
solution which contained 3000IU (75µg) vitamin D3 per spray and those allocated to PL received 
an oral spray solution that was identical in appearance, smell and taste but contained no vitamin 
D. The vitamin D3 content of the oral spray solution was independently verified using high 
performance liquid chromatography (Eurofins Product Testing, Cheshire, UK). Compliance was 
calculated using the weight of the bottle upon study completion (Todd et al., 2016). Gaelic 
footballers were instructed to self-administer a single spray daily for 12-weeks, specifically 
aiming at the buccal membrane to promote absorption. 
Sample collection 
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Blood samples were collected following an overnight fast and footballers were encouraged to 
continue drinking water. A trained phlebotomist obtained blood samples using a 21-gauge 
butterfly needle and 8mL serum separator and 9mL EDTA plasma vacutainer tubes (Greiner 
Bio-One GmbH, Kremsmunster, Austria).  Following inversion, plasma samples were placed in 
refrigeration until full blood profile analysis. Whole blood was separated by centrifugation at 
2200rpm for 15 minutes at 4°C. Following centrifugation, serum and plasma samples were 
pipetted into 0.5mL aliquots and stored at -80°C until further analysis.  
Blood analysis 
Serum total 25(OH)D [25(OH)D2 and 25(OH)D3] concentrations were determined using an API 
4000 liquid chromatography-tandem mass spectrometer (AB Sciex UK) at the Biochemistry 
Department, St. James’s Hospital Dublin. The laboratory is fully accredited and partakes in the 
vitamin D external quality assessment (DEQAS) scheme. Vitamin D was assayed using a 
commercially available kit (MassChrom® 25-OH-Vitamin D3; Chromsystems GmbH, Germany) 
with calibrators traceable to the National Institute of Standards and Technology (NIST) 
reference standards. Inter- and intra-assay coefficients of variation were 6.5% and 7.5% 
respectively. 
Plasma parathyroid hormone (PTH) concentrations were analysed, in duplicate, using a 
commercially available enzyme-linked immunosorbent assay (ELISA). Intra- and inter-assay 
coefficients of variation were 6.8% and 6.2% respectively. 
Full blood profiles were measured, as part of the original study, in whole blood within 2 hours of 
sample collection (Sysmex KX21-N, Sysmex Ltd, UK). EDTA tubes and the internal quality 
control tube were placed on a roller for 10 minutes at ambient temperature to ensure adequate 
mixing. Quality control tests were run daily, prior to analysis of EDTA samples. 
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Peripheral concentrations of Th1-derived cytokines (interferon-γ, TNF-α interleukins (IL)-1β, IL-
2, IL-6, IL-8, IL-12p70) and Th2-derived cytokines (IL-4, IL-10, and IL-13) were analysed in 
EDTA plasma using a multi-spot electrochemiluminescent assay according to the 
manufacturer’s instructions (Meso Scale Discovery, Gaithersburg, MD). The performance of this 
assay has been reported elsewhere (Dabitao et al., 2011). This assay was chosen owing to the 
broad range of pro- and anti-inflammatory cytokines included. For all cytokines that fell within 
range of the assay and are reported in the current paper, inter-assay coefficients of variation 
were below 10% and averaged 8.4% overall. 
High sensitivity C-reactive protein (hs-CRP), was quantified in serum using a clinical chemistry 
analyser in order to obtain a measure of systemic inflammation (ILab 650, Instrumentation 
Laboratory, Lexington, MA, USA). If a footballer’s hs-CRP concentration exceeded 10mg/L at 
either time point, this data was excluded because hs-CRP concentrations in excess of 10mg/L 
are indicative of acute infection (Ridker, 2003). 
Plasma LL-37 concentrations were analysed in duplicate using a commercially available 
enzyme-linked immunosorbent assay as this antimicrobial peptide is thought to be vitamin D-
regulated (Hycult Biotech, Fronstraat, The Netherlands). The assay was performed as per the 
manufacturer’s instructions with a 20x sample dilution. All samples fell within the range of the 
assay (0-100ng/mL) with intra- and inter-assay coefficients of variation of 13.9% and 5.4% 
respectively. 
 
Questionnaires 
All questionnaires were completed in the presence of a researcher. Physical activity (hours/day) 
was estimated using the validated Recent Physical Activity Questionnaire (Besson et al., 2010). 
Footballers completed this pre and post-intervention. Dietary vitamin D intake was estimated 
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using a validated food frequency questionnaire (Weir et al., 2016). Gaelic footballers answered 
questions relating to their intake of foods that contain vitamin D. Typical portion sizes of such 
foods were estimated using a photographic food atlas. 
Body composition 
The height and weight of Gaelic footballers was ascertained using a stadiometer and calibrated 
scales. Fat mass (FM) and fat-free mass (FFM) were also measured by whole body 
densitometry pre and post-intervention as part of the original study (BOD POD, Life 
Measurement Inc, Concord, CA). FM and FFM (kg) were adjusted for athlete’s height (m2) and 
presented as fat mass index (FMI) and fat-free mass index (FFMI) (kg/m2). 
Statistical analysis 
The Statistical Package for the Social Sciences (SPSS) was used to perform statistical analyses 
(IBM SPSS Statistics for Windows, version 21.0, IBM Corp, Armonk, NY). Statistical significance 
was set at P<0.05 throughout. Analyses were performed according to the intention-to-treat 
principle including all participants randomised to intervention (n=42) (Moher et al., 2010). The 
Shapiro-Wilk test was used to determine if data followed a normal distribution and skewed 
variables were transformed, using the logarithmic function, to attain a normal distribution prior to 
multiple imputation and further analysis. Transformations were applied to total 25(OH)D and all 
inflammatory biomarker concentrations. Descriptive statistics were used to present participant 
characteristics at baseline. Using an independent t-test or Chi-Square test, significant 
differences between treatment groups at baseline were identified. Analysis of covariance 
(ANCOVA) tested the effect of intervention on immune marker concentrations compared to the 
placebo group and adjusted for a priori covariates. In observational analysis, data from pre and 
post-intervention were pooled and an ANCOVA used to determine whether inflammatory 
biomarker concentrations varied according to the 75nmol/L proposed threshold for immune 
10 
 
 
function after adjusting for sex and FMI (Hart, 2012). Potential differences in the distribution of 
males and females between vitamin D status groups was tested using a Chi-square test. Post-
hoc power calculations were performed using the effect sizes generated from each ANCOVA 
model (GPower version 3.1). 
Results 
The participant flow is detailed in (Todd et al., 2016). A total of seven footballers were lost to 
follow up (n=5 VD and n=2 PL) due to sun holidays or injury/illness that was unrelated to the 
study. Physical and biochemical characteristics pre and post-intervention for VD and PL groups 
are provided in Table 1. At baseline, only 3 footballers presented with a total 25(OH)D 
concentration above 75nmol/L. Overall, 21 footballers exhibited vitamin D insufficiency (31-
49nmol/L) and 9 footballers exhibited clinical vitamin D deficiency (<30nmol/L) at baseline (Todd 
et al., 2016). Vitamin D3 supplementation increased total 25(OH)D by 79%; a significant 
increase compared to footballers allocated to PL (P=0.006), Figure 1. On average, footballers 
consumed 5.87±4.25µg vitamin D per day through dietary sources. There was no significant 
difference in the change over time in physical activity between VD and PL groups and therefore 
this variable was not included as a covariate in ANCOVA models. Concentrations of IL-1β and 
IL-4 were undetectable in all serum samples analysed and IL-2, IL-4, IL-6, IL-10, and IL-12p70 
concentrations fell below the lower limit of detection (LLOD) of the assay and were therefore 
excluded from statistical analyses. Using ANCOVA, it was determined that there was no 
significant effect of vitamin D3 supplementation on change over time in WBC, lymphocyte, 
neutrophil, hs-CRP, IL-8, TNF-α or LL-37 concentrations when compared to the PL group (all P 
>0.05). In observational analysis, there were 11 males and 11 females with 25(OH)D 
concentrations >75nmol/L, and 25 males and 37 females with 25(OH)D <75nmol/L. There was 
no significant difference in the distribution of males and females across these groups (P=0.294). 
Athletes with a vitamin D status above 75nmol/L exhibited significantly lower neutrophil and 
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WBC concentrations and significantly higher TNF-α and hs-CRP concentrations compared to 
those below 75nmol/L, Table 2. 
Discussion 
Whilst total 25(OH)D cut-offs for bone heath are well-established (Ross et al., 2011), no 
consensus has been met over what constitutes an ‘optimal’ total 25(OH)D concentration for 
extra-skeletal outcomes such as inflammation. Although it has been suggested that a total 
25(OH)D concentration in excess of 75nmol/L may be necessary in order to achieve immune-
related benefits (He et al., 2016; Laird et al., 2014), these thresholds are currently speculative 
owing to inconsistent results from randomised controlled trials (Barnes et al., 2011; Das et al., 
2014; He et al., 2015). Furthermore, it is not uncommon for cytokines to fall below the LLOD of 
a multiplex assay when samples are derived from healthy adults  (Kleiner et al., 2013).  A 
wealth of in vitro data lends support to an immunoregulatory role of 1,25(OH)2D (Cantorna et al., 
2004); although few have investigated the impact of vitamin D supplementation on inflammation 
in athletes in vivo (He et al., 2015; Lewis et al., 2013). Despite 93% of the cohort in the present 
study presenting with total 25(OH)D concentrations below 75nmol/L at baseline and an endpoint 
mean total 25(OH)D concentration of 84nmol/L, supplementation with vitamin D3 did not impact 
measures of inflammation including peripheral cytokine or antimicrobial peptide concentrations. 
This finding is comparable to that of Lewis et al. whose 6-month intervention (4000IU/100µg 
vitamin D3 daily) in collegiate swimmers and divers did not detect an effect of supplementation 
on TNF-α, IL-6 and IL-1β concentrations when compared to a placebo group (Lewis et al., 
2013). It is likely that vitamin D3 supplementation did not impact immune parameters in the 
current study because biomarkers were within their respective normal range, or at a 
concentration comparable to that of the general population at baseline (Black et al., 2004;Kim et 
al., 2011). It is plausible that vitamin D3 supplementation may only deliver an immunological 
benefit in those with a compromised immune system or underlying inflammation at baseline; a 
12 
 
 
concept supported by a recent review of randomised controlled trials (Cannell et al., 2014). For 
that reason, future placebo-controlled trials testing the immunological effects of vitamin D 
supplementation in healthy athletes may wish to consider obtaining blood samples immediately 
following high-intensity exercise. Emerging evidence suggests that this type of study design 
may be necessary in order to identify if vitamin D supplementation bolsters the compensatory 
anti-inflammatory cytokine response to high intensity exercise (Barker et al., 2013a;Pedersen, 
2000). 
Circulating LL-37 concentrations were similar to those reported in a large observational study of 
endurance athletes (He et al., 2013); yet universal reference ranges for this antimicrobial 
peptide have yet to be established and the clinical implications of LL-37 require further 
investigation. Vitamin D supplementation did not have an effect on LL-37 concentrations which 
contrasts with a recent vitamin D intervention trial conducted in male athletes (He et al., 2015). 
Over 14-weeks, He and colleagues reported a greater percentage increase in the LL-37 
concentration of athletes supplemented with 5000IU (125µg) vitamin D3 compared to athletes 
assigned to a placebo. However, when looking at absolute change, LL-37 concentrations 
increased significantly in both vitamin D-supplemented and placebo groups suggesting that use 
of percentage change, which does not account for variation between groups at baseline, may be 
masking a null result (Vickers, 2001). Furthermore, secondary analysis from a randomised 
controlled trial conducted in healthy females determined that vitamin D3 supplementation 
(60,000 IU weekly for 2 months followed by 60,000 IU fortnightly for six months) did not have an 
impact on the mRNA expression of LL-37 (Das et al., 2014). Such findings question whether 
theory driven by promising in vitro studies can be applied to intervention trials in a healthy 
athlete population. 
Observational findings have also been inconsistent with regard to the proposed link between 
vitamin D and inflammation in athletes and healthy adults (Dixon et al., 2012;Willis et al., 2012). 
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This is likely owing to statistically underpowered studies as well as differences in assay 
methodology, the type of athletes recruited and the total 25(OH)D cut-off used to categorise 
participants. Although the current study identified significant differences in neutrophil, WBC, 
TNF-α and hs-CRP concentrations between those with a vitamin D status ±75nmol/L; the 
abovementioned immune markers were within their respective normal range and so differences 
are unlikely to be clinically relevant. 
To our knowledge this is the first study to explore vitamin D and inflammation in Irish athletes. 
Despite being one of the largest vitamin D intervention trials in athletes to date, sample size was 
calculated to detect a significant change in VO2 max the primary outcome measure of the 
original study and not a significant change in inflammatory biomarkers. The current study was 
powered as follows to detect a significant change in WBC, 28%; lymphocytes, 50%; neutrophils, 
78%; LL-37, 13%; IL-8, 100%, TNF-α, 98% and hs-CRP,65%. Nonetheless, few have 
investigated the effects of vitamin D supplementation on inflammation in athletes and results of 
this study provide useful preliminary data to inform future adequately powered studies. A 
limitation of the current study is absence of an infection symptoms questionnaire and functional 
measures of immune function, such as response to an antigen challenge. Strengths of the study 
include the randomised controlled trial design, gender balance of athletes and the wide range of 
inflammatory biomarkers assessed. In conclusion, supplementation for 12-weeks with 3000IU 
(75µg) vitamin D3 per day did not have any effect on biomarkers of inflammation in this cohort of 
collegiate Gaelic footballers despite optimising vitamin D concentrations. 
Perspectives 
Based on the results of this study, it is clear that further research is necessary before vitamin D3 
supplementation can be deemed an important mediator of inflammation in healthy athletes. The 
current study demonstrated that restoring vitamin D status, from below 50nmol/L to above 
75nmol/L, does not influence circulating inflammatory biomarker concentrations; a conclusion 
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supported by a previous randomised controlled trial conducted in adolescent swimmers and 
divers (Lewis et al., 2013). Future vitamin D intervention studies in this area should focus on 
athlete cohorts at risk of a compromised immune system, those exhibiting underlying chronic 
inflammation, or sample athletes following vigorous exercise or rehabilitation from injury in order 
to establish any beneficial effects on inflammation. 
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Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Significant difference between treatment groups at baseline using an independent t test or chi-squared test (P<0.05). 
 
b Significant difference in change over time between treatment groups using an independent t test (P<0.05). 
 
Abbreviations: 25-hydroxyvitamin D, 25(OH)D; body mass index, BMI; parathyroid hormone, PTH; white blood cell count, WBC; 
interleukin, IL; tumour necrosis factor, TNF; cathelicidin antimicrobial peptide, LL-37; high-sensitivity C-reactive protein, hs-CRP; fat mass 
index, FMI; fat-free mass index, FFMI 
Table 1.  Physical and biochemical characteristics of Gaelic footballers at baseline and week 12 presented as mean ± SD 
Treatment group Vitamin D (n=22) Placebo (n=20)   
Measure Baseline Week 12 Baseline Week 12 P P 
General characteristics      
Age, y 20±2        - 20±2        - 0.819    - 
Height, cm 171.39±8.65        - 165.65±10.18        - 0.048a    - 
Weight, Kg 70.52±11.49 71.1±11.91 61.92±10.69 62.30±10.56 0.009a 0.493 
BMI, kg/m2 23.89±2.66 24.30±2.82 22.31±2.19 22.57±2.35 0.031a 0.605 
Physical activity, hr/day 1.06±1.04 0.70±0.59 0.88±0.89 0.51±0.47 0.466 0.749 
FMI, kg/m2 5.23±2.71 5.70±2.97 5.81±1.94 5.76±2.03 0.439 0.047b 
FFMI, kg/m2 18.95±3.11 18.34±2.51 16.46±1.88 16.89±2.12 0.004 a 0.082 
Vitamin D intake, µg/day 6.73±5.33       - 4.93±2.47        - 0.227    - 
PTH, pg/mL 41.21±15.98 42.24±20.96 39.28±19.12 43.93±23.65 0.502 0.204 
Adjusted calcium, mmol/L 2.29±0.07 2.29±0.09 2.29±0.08 2.31±0.08 0.961 0.427 
       
Inflammation       
WBC count, x103/µL 5.78±1.63 5.77±1.60 5.94±1.13 5.83±1.09 0.551 0.766 
Lymphocytes, x103/µL 1.96±0.48 1.77±0.56 1.95±0.55 1.76±0.50 0.885 0.727 
Neutrophils, x103/µL 3.36±1.38 3.54±1.42 3.47±0.88 3.57±1.07 0.426 0.756 
IL-8, pg/mL 5.36±2.80 4.59±1.18 4.61±1.31 4.90±1.47 0.347 0.101 
TNF-α, pg/mL 2.15±0.42 5.61±1.51 2.01±0.60 5.95±1.63 0.271 0.422 
LL-37, ng/mL 36.21±13.43 29.69±21.50 36.94±24.75 21.71±27.86 0.033 a 0.347 
hs-CRP, mg/L 1.01±1.28 1.81±2.99 1.90±1.45 2.81±4.85 0.979 0.474 
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a Differences between groups assessed using an independent t test or chi-squared test 
b Differences between groups assessed using an ANCOVA adjusting for FMI and sex  
c Statistically significant difference between vitamin D status groups P<0.05 
d Statistically significant difference between vitamin D status groups P<0.001 
 
Abbreviations: 25-hydroxyvitamin D, 25(OH)D; body mass index, BMI; parathyroid hormone, PTH; fat mass index, FMI; white blood cell 
count, WBC; interleukin, IL; tumour necrosis factor, TNF; cathelicidin antimicrobial peptide, LL-37, high-sensitivity C-reactive protein, hs-
CRP; fat mass index, FMI; fat-free mass index, FFMI. 
 
.
Table 2. Characteristics of footballers according to total 25(OH)D concentrations above and 
below 75nmol/L with values provided as mean ± SD (pooled data) 
  Total 25(OH)D concentration   
Measure <75nmol/L (n=62) >75nmol/L (n=22) P 
General characteristics a 
Age, y 20±2 20±2 0.846 
BMI, kg/m2 23.17±2.56 23.60±2.94 0.544 
Physical activity, hr/day 0.75±0.72 0.79±0.97 0.749 
FMI, kg/m2 5.68±2.31 5.55±2.79 0.597 
FFMI, kg/m2 17.61±2.68 18.03±2.40 0.467 
Total 25(OH)D, nmol/L 43.34±13.22 92.92±19.07 0.001 d 
PTH, pg/mL 41.63±18.46 41.76±14.08 0.823 
Adjusted calcium, mmol/L 2.30±0.07 2.27±0.53 0.122 
 
Inflammationb 
WBC count, x103/µL 6.00±1.28 5.33±1.39 0.034 c 
Lymphocytes, x103/µL 1.87±0.49 1.81±0.50 0.594 
Neutrophils, x103/µL 3.65±1.18 3.03±1.01 0.028 c 
LL-37, ng/mL 31.02±21.68 31.80±18.91 0.522 
IL-8, pg/mL 4.88±1.92 4.82±1.41 0.919 
TNF-α, pg/mL 3.38±2.08 5.28±1.57 0.001 d 
hs-CRP, mg/L 1.57±2.83 2.03±2.07 0.025 c 
17 
 
 
Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Total 25(OH)D response to intervention versus placebo presented as mean (95% CI). 
Daily supplementation for 12-weeks with 3000IU (75µg) vitamin D3 increased mean total 
25(OH)D concentration from 47 to 84nmol/L (+79%) compared with 43 to 49nmol/L (+14%) in 
those allocated to placebo (ANCOVA, P= 0.006). 
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